| 产品描述： | Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research |
| 靶点： |
Ser/Thr Protease |
| 体外研究： |
C1 inhibitor (C1INH) is the primary regulator of contact activation, both by inhibiting the conversion of prekallikrein to plasma kallikrein (PKK) by FXIIa, and by directly inhibiting PKK. PKK cleaves high molecular weight kininogen, releasing bradykinin, whose actions are responsible for the signs and symptoms of hereditary angioedema (HAE) |
| 参考文献： |
1. Aygoren-Pursun E, et al. Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat. J Allergy Clin Immunol. 2016 Sep;138(3):934-936.e5. 2. Cornpropst M, et al. Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study. Allergy. 2016;71(12):1676-1683. |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.947 ml |
9.736 ml |
19.473 ml |
| 5 mM |
0.389 ml |
1.947 ml |
3.895 ml |
| 10 mM |
0.195 ml |
0.974 ml |
1.947 ml |
| 50 mM |
0.039 ml |
0.195 ml |
0.389 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京